The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens
Open accessAbstract
Traditional methods employed to discover new antibiotics are both a time-consuming and financially-taxing venture. This has led researchers to mine existing libraries of clinical molecules in order to repurpose old drugs for new applications (as antimicrobials). Such an effort led to the discovery of auranofin, a drug initially approved as an anti-rheumatic agent, which also possesses potent antibacterial activity in a clinically achievable range. The present study demonstrates auranofin’s antibacterial activity is a complex process that involves inhibition of multiple biosynthetic pathways including cell wall, DNA, and bacterial protein synthesis. We also confirmed that the lack of activity of auranofin observed against Gram-negative bacteria is due to the permeability barrier conferred by the outer membrane. Auranofin’s ability to suppress bacterial protein synthesis leads to significant reduction in the production of key methicillin-resistant Staphylococcus aureus (MRSA) toxins. Additionally, auranofin is capable of eradicating intracellular MRSA present inside infected macrophage cells. Furthermore, auranofin is efficacious in a mouse model of MRSA systemic infection and significantly reduces the bacterial load in murine organs including the spleen and liver. Collectively, this study provides valuable evidence that auranofin has significant promise to be repurposed as a novel antibacterial for treatment of invasive bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Gillet, Y., Issartel, B., Vanhems, P., Fournet, J.-C., Lina, G., Bes, M., Vandenesch, F., Piémont, Y., Brousse, N., Floret, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07877-7 · Cited by 1,514
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Cited by
New Antimicrobial Strategies Based on Metal Complexes
Claudel, M., Schwarte, J. V., & Fromm, K. M. (2020) · Chemistry · doi:10.3390/chemistry2040056 · Cited by 344
Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective
Sultan, I., Rahman, S., Jan, A. T., Siddiqui, M. T., Mondal, A. H., & Haq, Q. M. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02066 · Cited by 320
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Thangamani, S., Maland, M., Mohammad, H., Pascuzzi, P. E., Avramova, L., Koehler, C. M., Hazbun, T. R., & Seleem, M. N. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00004 · Cited by 90
Self-citation
Metadata
- Authors
- Thangamani, S., Mohammad, H., Abushahba, M. F. N., Sobreira, T. J. P., Hedrick, V. E., Paul, L. N., & Seleem, M. N.
- Venue
- Scientific Reports
- Published
- 2016-03-03
- Volume
- 6
- Issue
- 1
- Pages
- 22571-22571
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2321970843
- Cited by
- 211
- References
- 4
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. https://app.cochat.ai/papers/10.1038/srep22571
- The paper
- Thangamani, S., Mohammad, H., Abushahba, M. F. N., Sobreira, T. J. P., Hedrick, V. E., Paul, L. N., & Seleem, M. N. (2016). Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. Scientific Reports. https://doi.org/10.1038/srep22571
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.